Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diosmin for Non-diabetic NASH
NCT05942547Phase 3Unknown
- Sponsor
- Tanta University
- Start
- Jul 2023
- Primary completion
- Oct 2023
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) comparing Diosmin Group with Placebo Group (2 arms). Primary endpoints: NAFLD Fibrosis Score at 3 months and Fibrosis Risk Score at 3 months. Status: unknown.
02
Drugs
diosmin
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05942547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05942547.